Pressmeddelanden

PILA PHARMA: CEO GUSTAV H. GRAM ACQUIRES ADDITIONAL SHARES PILA PHARMA AB (publ) (FN STO: PILA), an innovative biotech company developing novel oral drugs based on TRPV1 inhibition for treatment of obesity and diabetes, informs investors...
REG MAR
PILA PHARMA ENTERS INTO AGREEMENT WITH THE CRO GUBRA ON PRECLINICAL TRIALS OF XEN-D0501 IN OBESITY PILA PHARMA AB (publ) (FN STO: PILA), an innovative biotech company developing novel oral drugs for treatment of obesity and diabetes based on TRPV1 inhibition, informs investors...
PILA PHARMA TO PARTICIPATE AT THE 61ST EASD DIABETES & OBESITY SCIENTIFIC MEETING, NEXT WEEK 16-19 SEPTEMBER IN VIENNA PILA PHARMA AB (publ) (FN STO: PILA), an innovative biotech company developing novel oral drugs based on TRPV1 inhibition for treatment of obesity and diabetes, informs investors...
PILA PHARMA: ALL H1 REPORT & INVESTOR INTERVIEWS NOW ONLINE PILA PHARMA AB (publ) (FN STO: PILA), an innovative biotech company developing novel oral drugs based on TRPV1 inhibition for treatment of obesity and diabetes, informs investors...
PILA PHARMA: H1 REPORT INTERVIEW RECORDING WITH DIREKT STUDIOS - CEO COMMENTS ON HEAVILY OVERSUBSCRIBED RIGHTS ISSUE AND PLANS PILA PHARMA AB (publ) (FN STO: PILA), an innovative biotech company developing novel oral drugs based on TRPV1 inhibition for treatment of obesity and diabetes, informs investors...
PILA PHARMA: CEO VISITS INVESTMENT PODCAST 10X TO COMMENT ON HEAVILY OVERSUBSCRIBED ISSUE (293,5%) AND OBESITY PLANS PILA PHARMA AB (publ) (FN STO: PILA), an innovative biotech company developing novel oral drugs based on TRPV1 inhibition for treatment of obesity and diabetes, informs investors...
Visa fler pressmeddelanden

Rapporter

Datum Rubrik
Interim Report H1 2025
Annual Report 2024
Year-end report 2024

Video

Finansiell kalender

Om PILA PHARMA

Prenumerera

Få löpande information från PILA PHARMA via e-post.

Språk
Nyhetstyper

Handelsinformation

Kurs ()
Förändring ()
Marknad Nasdaq First North Growth Market Kortnamn PILA ISIN-kod SE0015988274 Certified Adviser Aqurat Fondkommission